THE BEST SIDE OF TRASTUZUMAB DERUXTECAN COPYRIGHT

One of the most underneath-investigated “driving forces” involved in trastuzumab resistance is PTEN. Nagata et al. (2004) described the loss of PTEN was noticed in 36% of HER2-positive Major breast tumor specimens from people with phase IV disease. On top of that, they also confirmed that individuals with PTEN-deficient tumors experienced remar